

**Baxter International Inc.**  
**Reclassified Key Product Line GAAP Sales - US/International**  
**2012, 2011, & 2010<sup>1</sup>**  
(unaudited)  
(\$ in millions)

	2012 Sales			2012 Sales			2012 Sales			2012 Sales			2012 Sales		
	US	International	Total	US	International	Total	US	International	Total	US	International	Total	US	International	Total
<b>BioScience</b>															
Hemophilia <sup>2</sup>	\$310	\$433	\$743	\$328	\$501	\$829	\$346	\$436	\$782	\$336	\$551	\$887	\$1,320	\$1,921	\$3,241
BioTherapeutics <sup>3</sup>	328	170	498	318	166	484	347	169	516	374	197	571	1,367	702	2,069
BioSurgery <sup>4</sup>	87	67	154	101	73	174	97	68	165	102	78	180	387	286	673
Vaccines <sup>5</sup>	0	67	67	0	79	79	0	59	59	13	36	49	13	241	254
<b>Total BioScience</b>	<b>\$725</b>	<b>\$737</b>	<b>\$1,462</b>	<b>\$747</b>	<b>\$819</b>	<b>\$1,566</b>	<b>\$790</b>	<b>\$732</b>	<b>\$1,522</b>	<b>\$825</b>	<b>\$862</b>	<b>\$1,687</b>	<b>\$3,087</b>	<b>\$3,150</b>	<b>\$6,237</b>
<b>Medical Products</b>															
Fluid Systems <sup>6</sup>	\$374	\$346	\$720	\$380	\$360	\$740	\$354	\$348	\$702	\$380	\$395	\$775	\$1,488	\$1,449	\$2,937
Renal <sup>7</sup>	97	491	588	98	537	635	100	529	629	109	566	675	404	2,123	2,527
Specialty Pharmaceuticals <sup>8</sup>	172	196	368	161	203	364	169	198	367	171	205	376	673	802	1,475
BioPharma Solutions <sup>9</sup>	100	150	250	117	150	267	100	157	257	87	153	240	404	610	1,014
<b>Total Medical Products</b>	<b>\$743</b>	<b>\$1,183</b>	<b>\$1,926</b>	<b>\$756</b>	<b>\$1,250</b>	<b>\$2,006</b>	<b>\$723</b>	<b>\$1,232</b>	<b>\$1,955</b>	<b>\$747</b>	<b>\$1,319</b>	<b>\$2,066</b>	<b>\$2,969</b>	<b>\$4,984</b>	<b>\$7,953</b>
<b>TOTAL BAXTER</b>	<b>\$1,468</b>	<b>\$1,920</b>	<b>\$3,388</b>	<b>\$1,503</b>	<b>\$2,069</b>	<b>\$3,572</b>	<b>\$1,513</b>	<b>\$1,964</b>	<b>\$3,477</b>	<b>\$1,572</b>	<b>\$2,181</b>	<b>\$3,753</b>	<b>\$6,056</b>	<b>\$8,134</b>	<b>\$14,190</b>

	2011 Sales			2011 Sales			2011 Sales			2011 Sales			2011 Sales		
	US	International	Total	US	International	Total	US	International	Total	US	International	Total	US	International	Total
<b>BioScience</b>															
Hemophilia <sup>2</sup>	\$280	\$440	\$720	\$292	\$526	\$818	\$304	\$515	\$819	\$309	\$550	\$859	\$1,185	\$2,031	\$3,216
BioTherapeutics <sup>3</sup>	323	157	480	316	185	501	317	173	490	343	188	531	1,299	703	2,002
BioSurgery <sup>4</sup>	78	62	140	78	69	147	78	65	143	81	69	150	315	265	580
Vaccines <sup>5</sup>	3	65	68	1	86	87	0	65	65	2	33	35	6	249	255
<b>Total BioScience</b>	<b>\$684</b>	<b>\$724</b>	<b>\$1,408</b>	<b>\$687</b>	<b>\$866</b>	<b>\$1,553</b>	<b>\$699</b>	<b>\$818</b>	<b>\$1,517</b>	<b>\$735</b>	<b>\$840</b>	<b>\$1,575</b>	<b>\$2,805</b>	<b>\$3,248</b>	<b>\$6,053</b>
<b>Medical Products</b>															
Fluid Systems <sup>6</sup>	\$379	\$352	\$731	\$367	\$388	\$755	\$358	\$376	\$734	\$370	\$383	\$753	\$1,474	\$1,499	\$2,973
Renal <sup>7</sup>	96	491	587	97	536	633	96	550	646	96	568	664	385	2,145	2,530
Specialty Pharmaceuticals <sup>8</sup>	130	171	301	149	189	338	138	188	326	171	192	363	588	740	1,328
BioPharma Solutions <sup>9</sup>	133	124	257	118	139	257	112	144	256	94	145	239	457	552	1,009
<b>Total Medical Products</b>	<b>\$738</b>	<b>\$1,138</b>	<b>\$1,876</b>	<b>\$731</b>	<b>\$1,252</b>	<b>\$1,983</b>	<b>\$704</b>	<b>\$1,258</b>	<b>\$1,962</b>	<b>\$731</b>	<b>\$1,288</b>	<b>\$2,019</b>	<b>\$2,904</b>	<b>\$4,936</b>	<b>\$7,840</b>
<b>TOTAL BAXTER</b>	<b>\$1,422</b>	<b>\$1,862</b>	<b>\$3,284</b>	<b>\$1,418</b>	<b>\$2,118</b>	<b>\$3,536</b>	<b>\$1,403</b>	<b>\$2,076</b>	<b>\$3,479</b>	<b>\$1,466</b>	<b>\$2,128</b>	<b>\$3,594</b>	<b>\$5,709</b>	<b>\$8,184</b>	<b>\$13,893</b>

	2010 Sales			2010 Sales			2010 Sales			2010 Sales			2010 Sales		
	US	International	Total	US	International	Total	US	International	Total	US	International	Total	US	International	Total
<b>BioScience</b>															
Hemophilia <sup>2</sup>	\$274	\$437	\$711	\$292	\$441	\$733	\$300	\$455	\$755	\$299	\$514	\$813	\$1,165	\$1,847	\$3,012
BioTherapeutics <sup>3</sup>	273	145	418	268	155	423	286	169	455	319	205	524	1,146	674	1,820
BioSurgery <sup>4</sup>	62	57	119	76	57	133	79	51	130	83	62	145	300	227	527
Vaccines <sup>5</sup>	1	113	114	0	69	69	1	46	47	2	49	51	4	277	281
<b>Total BioScience</b>	<b>\$610</b>	<b>\$752</b>	<b>\$1,362</b>	<b>\$636</b>	<b>\$722</b>	<b>\$1,358</b>	<b>\$666</b>	<b>\$721</b>	<b>\$1,387</b>	<b>\$703</b>	<b>\$830</b>	<b>\$1,533</b>	<b>\$2,615</b>	<b>\$3,025</b>	<b>\$5,640</b>
<b>Medical Products</b>															
Fluid Systems <sup>6,10</sup>	\$133	\$336	\$469	\$376	\$346	\$722	\$382	\$341	\$723	\$384	\$387	\$771	\$1,275	\$1,410	\$2,685
Renal <sup>7</sup>	95	489	584	98	487	585	99	495	594	101	525	626	393	1,996	2,389
Specialty Pharmaceuticals <sup>8</sup>	132	161	293	136	170	306	148	161	309	150	188	338	566	680	1,246
BioPharma Solutions <sup>9</sup>	110	109	219	109	114	223	94	117	211	102	128	230	415	468	883
<b>Total Medical Products</b>	<b>\$470</b>	<b>\$1,095</b>	<b>\$1,565</b>	<b>\$719</b>	<b>\$1,117</b>	<b>\$1,836</b>	<b>\$723</b>	<b>\$1,114</b>	<b>\$1,837</b>	<b>\$737</b>	<b>\$1,228</b>	<b>\$1,965</b>	<b>\$2,649</b>	<b>\$4,554</b>	<b>\$7,203</b>
<b>TOTAL BAXTER</b> <sup>10</sup>	<b>\$1,080</b>	<b>\$1,847</b>	<b>\$2,927</b>	<b>\$1,355</b>	<b>\$1,839</b>	<b>\$3,194</b>	<b>\$1,389</b>	<b>\$1,835</b>	<b>\$3,224</b>	<b>\$1,440</b>	<b>\$2,058</b>	<b>\$3,498</b>	<b>\$5,264</b>	<b>\$7,579</b>	<b>\$12,843</b>

<sup>1</sup> Effective January 1, 2013, Baxter is transitioning to a commercial franchise structure for reporting net sales. Net sales in 2012, 2011, and 2010 have been reclassified to reflect the new commercial franchise structure. See Notes 2 - 9 below for a description of each commercial franchise.

<sup>2</sup> Includes sales of recombinant FVIII products (ADVATE and RECOMBINATE) and plasma-derived hemophilia products (primarily FVII, FVIII and FEIBA). Recombinant and plasma-based products were previously reported separately.

<sup>3</sup> Includes sales of the company's liquid formulation of the antibody-replacement therapy immunoglobulin product (GAMMAGARD LIQUID) and other plasma-based therapies such as albumin and alpha-1 antitrypsin products. Antibody therapies and plasma-based products were previously reported separately.

<sup>4</sup> Consists of biological products and delivery devices used for hemostasis, tissue sealing, adhesion reduction, hard tissue regeneration, as well as soft tissue repair and microsurgery products.

<sup>5</sup> Consists of vaccines for seasonal and pandemic influenza, as well as meningitis C, and tick-borne encephalitis.

<sup>6</sup> Principally includes IV therapies, infusion pumps, administration sets, and premixed drugs platforms. IV therapies were previously reported with nutrition products in IV Therapies, and Infusion Systems and Global Injectables were previously reported separately.

<sup>7</sup> Consists of PD and HD therapies.

<sup>8</sup> Principally includes nutrition and anesthesia products. Nutrition products were previously reported with IV therapies in IV Therapies and anesthesia products were previously reported separately.

<sup>9</sup> Principally includes sales from the pharmaceutical partnering business and pharmacy compounding services, which were previously reported with Global Injectables. Also includes revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the Transfusion Therapies business after the February 2007 divestiture, which had previously been reported separately.

<sup>10</sup> GAAP net sales in the first quarter and full year of 2010 included a charge of \$213 million related to the recall of COLLEAGUE infusion pumps. Refer to following page for a reconciliation of adjusted sales excluding the COLLEAGUE infusion pump charge to GAAP net sales.

**Baxter International Inc.**  
**Reconciliation of GAAP to Non-GAAP Net Sales Measures**  
**Quarterly and Full Year 2010<sup>1</sup>**  
**(unaudited)**  
**(\$ in millions)**

The company's GAAP net sales for the first quarter and full year 2010 included a \$213 million charge related to the recall of COLLEAGUE infusion pumps, which impacted GAAP net sales as follows:

	Q1 2010			Q2 2010			Q3 2010			Q4 2010			Total 2010		
	US	International	Total	US	International	Total	US	International	Total	US	International	Total	US	International	Total
<b>Fluid Systems - GAAP</b>	\$133	\$336	\$469	\$376	\$346	\$722	\$382	\$341	\$723	\$384	\$387	\$771	\$1,275	\$1,410	\$2,685
COLLEAGUE infusion pump charge	213	-	213	-	-	-	-	-	-	-	-	-	213	-	213
<b>Fluid Systems - Adjusted</b>	<b>\$346</b>	<b>\$336</b>	<b>\$682</b>	<b>\$376</b>	<b>\$346</b>	<b>\$722</b>	<b>\$382</b>	<b>\$341</b>	<b>\$723</b>	<b>\$384</b>	<b>\$387</b>	<b>\$771</b>	<b>\$1,488</b>	<b>\$1,410</b>	<b>\$2,898</b>
<b>Total Medical Products - GAAP</b>	\$470	\$1,095	\$1,565	\$719	\$1,117	\$1,836	\$723	\$1,114	\$1,837	\$737	\$1,228	\$1,965	\$2,649	\$4,554	\$7,203
COLLEAGUE infusion pump charge	213	-	213	-	-	-	-	-	-	-	-	-	213	-	213
<b>Total Medical Products - Adjusted</b>	<b>\$683</b>	<b>\$1,095</b>	<b>\$1,778</b>	<b>\$719</b>	<b>\$1,117</b>	<b>\$1,836</b>	<b>\$723</b>	<b>\$1,114</b>	<b>\$1,837</b>	<b>\$737</b>	<b>\$1,228</b>	<b>\$1,965</b>	<b>\$2,862</b>	<b>\$4,554</b>	<b>\$7,416</b>
<b>TOTAL BAXTER - GAAP</b>	\$1,080	\$1,847	\$2,927	\$1,355	\$1,839	\$3,194	\$1,389	\$1,835	\$3,224	\$1,440	\$2,058	\$3,498	\$5,264	\$7,579	\$12,843
COLLEAGUE infusion pump charge	213	-	213	-	-	-	-	-	-	-	-	-	213	-	213
<b>TOTAL BAXTER - Adjusted</b>	<b>\$1,293</b>	<b>\$1,847</b>	<b>\$3,140</b>	<b>\$1,355</b>	<b>\$1,839</b>	<b>\$3,194</b>	<b>\$1,389</b>	<b>\$1,835</b>	<b>\$3,224</b>	<b>\$1,440</b>	<b>\$2,058</b>	<b>\$3,498</b>	<b>\$5,477</b>	<b>\$7,579</b>	<b>\$13,056</b>

<sup>1</sup> GAAP net sales in 2011 and 2012 were not impacted by any special charges.